Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Liabilities and Shareholders Equity (2016 - 2025)

Abeona Therapeutics has reported Liabilities and Shareholders Equity over the past 15 years, most recently at $219.6 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $219.6 million for Q4 2025, up 101.57% from a year ago — trailing twelve months through Dec 2025 was $796.3 million (up 81.65% YoY), and the annual figure for FY2025 was $219.6 million, up 101.57%.
  • Liabilities and Shareholders Equity for Q4 2025 was $219.6 million at Abeona Therapeutics, down from $231.1 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for ABEO hit a ceiling of $246.2 million in Q2 2025 and a floor of $38.8 million in Q3 2022.
  • Median Liabilities and Shareholders Equity over the past 5 years was $89.5 million (2021), compared with a mean of $107.3 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: crashed 67.43% in 2022 and later skyrocketed 150.24% in 2024.
  • Abeona Therapeutics' Liabilities and Shareholders Equity stood at $79.6 million in 2021, then fell by 19.31% to $64.2 million in 2022, then dropped by 0.33% to $64.0 million in 2023, then skyrocketed by 70.2% to $108.9 million in 2024, then skyrocketed by 101.57% to $219.6 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $219.6 million (Q4 2025), $231.1 million (Q3 2025), and $246.2 million (Q2 2025) per Business Quant data.